Inbrija supportive care for viral infection

Discussion in 'Acorda Therapeutics' started by anonymous, Mar 12, 2020 at 10:49 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    With the current dip in ACOR to $0.87 and still sinking hope Ron makes a deal soon. PFE has bukku cash so ACOR purchase would be chump change if decide not to swap shares. Ron can hopefully negotiate a sweet position for himself and Laura as well as a board seats. We bottom feeders will get the leftovers.
     

  2. anonymous

    anonymous Guest

    you really think your made up M&A is going to save this place?

    PFE wouldn’t touch ACOR and RC has a better chance at being a Nobel winner than being CEO of anything larger than his current debacle.

    Happy Trails little buddy.
     
  3. anonymous

    anonymous Guest

    A suggestion (yes, Ron reads CP)

    In the current environment, it is unlikely that a successful IPO will occur.
    Acorda should find a rising CNS Biotech and offer to merge.
    A win-win, as Acorda Investors will get now get a true pipeline; and the other Investors get an exit with minimal dilution. There are a handful of Parkinson's biotechs in that position.
     
  4. anonymous

    anonymous Guest

    what exactly does ACOR bring to the table in this fantasy scenario?

    if a company is looking for cash, the solution isn’t to partner up with a failed Pharma company circling the drain with revenue, cash and restructured debt problems of their own.

    your solution is akin to transferring passengers from the Lusitania to the Titanic
     
  5. anonymous

    anonymous Guest

    Hey dummy, Acorda is richly endowed with seasoned and proven pharma professionals, not just RC and LS but right down the line to you and me. Pfiza has had a plethora of dimwitted managers and is eying Acorda and other smaller acquisitions for an infusion of raw talent.
     
  6. anonymous

    anonymous Guest

    you might want to get checked for the Wuhan.

    clearly your febrile state is making you hallucinate that PFE would
    A) want Inbrija and
    B) keep anyone here above the manager level.

    that isn’t how they work, nor is it how this will go down.
     
  7. anonymous

    anonymous Guest

    Any Pfizer news ?
     
  8. anonymous

    anonymous Guest

    Yes! Didn’t you see the headline?!

    Please... there is no Pfizer news except them working on a vaccine. this is the dumbest ploy ever.
     
  9. anonymous

    anonymous Guest

    Where is the Pfizer headline ? I looked everywhere ??
     
  10. anonymous

    anonymous Guest

    No headlines... nobody’s going to buy this pig, if they do, your luck to get $1.00 per share buy out. 98% less than your all time high of $40.
    Your leader is a genius
     
  11. anonymous

    anonymous Guest

    No way, Blank has a plan to drive it up, should reach $2-$3. Much better than 80 cents. If the inhaled LD brakethru occurs then much more.
     
  12. anonymous

    anonymous Guest

    habib, there was a time you were prognosticating $60+ per share. Now here you are trying to pump a buck or two.

    did it ever occur to you that you just aren’t very good at this?
     
  13. anonymous

    anonymous Guest

    What kind of cars do Pfizer reps have ? Is there a choice or is like Ford Fiesta ? It better be a good car if we're gonna stay after the deal
     
  14. anonymous

    anonymous Guest

    If, and I stress IF , anyone buys you, it will be for IP only, and new owners will not need a circus tent of bumbling idiots who fumbled this launch and many other deliverables. Call Habib, maybe he can give you a job.
     
  15. anonymous

    anonymous Guest

    Acorda should consider moving into a virtual sales force and make lemonade out of the Covid-19 situation.

    No need for visiting reps with cars anymore. Why not just outsource the sales force to a virtual studio in Mumbai or Tijuana and improve the profit margins on the few units of Inbrija that are being sold?
     
  16. anonymous

    anonymous Guest

    Very profound question. Understand Pfizer in fact offers their sales team a flat transportation voucher worth $47k every two years for auto lease/purchase. That said why would they award a no-op from Acorda ?

    Also typically make all acquired reps "reapply" for their position. That levels the playing field and facilitates load dumping. Very prudent approach I must say,
     
  17. anonymous

    anonymous Guest

    You must be a crackhead...are you that stupid? 47k for 2 years.... HA, what a jackass you are!
     
  18. anonymous

    anonymous Guest

    you must be one of the leftover under-performers....as your focused on a proposed vouched for a vehicle???? This trivial focus was the driver for Acorda colossal failures... if Pfizer or anyone decides to buy you.. it is for the product only... not for any sales or support people... Pfizer has all the infrastructure they need and can and will relaunch this better than Acorda ever could. Any accordions are a toxic plague and has no role with any new owner....Thank your lucky stars if you get a severance...